Ticker Details
Wave Life Sciences Ltd. Ordinary Shares WAVE Life Sciences Ltd is a preclinical therapeutics developer in Singapore. Its pipeline of drugs is intended to cure rare genetic disorders such as Huntington, duchenne muscular dystrophy (DMD) and inflammatory bowel disease.
IPO Date:	November 11, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.35B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.47 | 3.34%
Avg Daily Range (30 D):	$0.32 | 3.26%
Avg Daily Range (90 D):	$0.52 | 3.87%

Institutional Daily Volume
Avg Daily Volume:	.68M
Avg Daily Volume (30 D):	4.53M
Avg Daily Volume (90 D):	5.66M

Trade Size
Avg Trade Size (Sh.):	108
Avg Trade Size (Sh.) (30 D):	125
Avg Trade Size (Sh.) (90 D):	119

Institutional Trades
Total Institutional Trades:	1,570
Avg Institutional Trade:	$1.68M
Avg Institutional Trade (30 D):	$2.38M
Avg Institutional Trade (90 D):	$2.29M
Avg Institutional Trade Volume:	.15M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.2M
Avg Closing Trade (30 D):	$4.67M
Avg Closing Trade (90 D):	$4.91M
Avg Closing Volume:	210.27K

News

Feb 2, 2026 @ 7:16 PM Wave Life Sciences Reclaims Rare Disease Drug From... Source: Vandana Singh

Dec 11, 2025 @ 7:01 AM Golden Cross Alert: 3 Stocks With Major Upside Pot... Source: Chris Markoch

Dec 10, 2025 @ 2:50 AM Wave Life Sciences Prices Upsized $350 Million Pub... Source: Wave Life Sciences

Dec 10, 2025 @ 12:19 AM Why Wave Life Sciences Stock Crushed it Again Toda... Source: Eric Volkman

Dec 8, 2025 @ 11:30 PM Why Wave Life Sciences Stock Vaulted 146% Higher o... Source: Eric Volkman

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-1.21	$-.29	$-1.21
Diluted EPS	$-1.21	$-.29	$-1.21
Revenue	$42.73M	$17.25M	$42.73M
Gross Profit
Net Income / Loss	$-204.38M	$-53.18M	$-204.38M
Operating Income / Loss	$-215.38M	$-56.47M	$-215.38M
Cost of Revenue
Net Cash Flow	$300.02M	$405.92M	$300.02M
PE Ratio